Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Lawrence · SciRah

Researcher profile · Semantic Scholar

D. Lawrence

Share profile

D. Lawrence — researcher profile on SciRah

h-index: 52
Works: 179
Citations: 18K

Most-cited papers

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed S Mahmood, M. Fradley, J. Cohen, A. Nohria +16 more
2018Journal of the American College of Cardiology1,494 citations Open access
Semantic Scholar
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
A. Ribas, O. Hamid, A. Daud, F. Hodi +24 more
2016Journal of the American Medical Association (JAMA)1,038 citations Open access
Semantic Scholar
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
M. Sade-Feldman, Yunxin J. Jiao, Jonathan H. Chen, Michael S. Rooney +27 more
2017Nature Communications898 citations Open access
Semantic Scholar
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.
Douglas B. Johnson, R. Sullivan, P. Ott, M. Carlino +17 more
2016JAMA Oncology610 citations Open access
Semantic Scholar
Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis.
Lili Zhang, Magid Awadalla, Syed S Mahmood, A. Nohria +40 more
2020European Heart Journal317 citations Open access
Semantic Scholar
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
A. Ribas, D. Lawrence, V. Atkinson, S. Agarwal +13 more
2019Nature Medicine304 citations Open access
Semantic Scholar
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
J. Weber, G. Gibney, R. Sullivan, J. Sosman +13 more
2016The Lancet Oncology304 citations Open access
Semantic Scholar
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.
G. Long, J. Weber, J. Infante, Kevin B. Kim +22 more
2016Journal of Clinical Oncology290 citations
Semantic Scholar
Global Longitudinal Strain and Cardiac Events in Patients with Immune Checkpoint Inhibitor-Related Myocarditis
Magid Awadalla, Syed S Mahmood, J. Groarke, Malek Z O Hassan +38 more
2020Journal of the American College of Cardiology266 citations Open access
Semantic Scholar
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
D. Dubey, W. David, K. Reynolds, D. Chute +6 more
2020Annals of Neurology196 citations
Semantic Scholar
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.
A. Betof, R. Nipp, A. Giobbie-Hurder, Romany A. N. Johnpulle +6 more
2017The Oncologist183 citations Open access
Semantic Scholar
Angiopoietin-2 as a biomarker and target for immune checkpoint therapy
Xin-Qi Wu, A. Giobbie-Hurder, Xiao-Yun Liao, Courtney F. Connelly +14 more
2016Cancer immunology research154 citations Open access
Semantic Scholar
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy
Xue Bai, Jia-Ni Hu, Allison Betof Warner, Henry T. Quach +29 more
2021Clinical Cancer Research152 citations Open access
Semantic Scholar
Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies
D. Dubey, W. David, A. Amato, K. Reynolds +7 more
2019Neurology136 citations
Semantic Scholar
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
P. Brastianos, E. Lee, J. Cohen, S. Tolaney +28 more
2020Nature Medicine129 citations
Semantic Scholar
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
A. Tarhini, Sandra J. Lee, F. Hodi, U. Rao +17 more
2019Journal of Clinical Oncology127 citations Open access
Semantic Scholar
Evolution of Delayed Resistance to Immunotherapy in a Melanoma Responder
David Liu, Jia-Ren Lin, Emily J Robitschek, Gyulnara G. Kasumova +36 more
2021Nature Medicine115 citations Open access
Semantic Scholar
A Phase II Trial of Dasatinib in Patients with Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2607)
K. Kalinsky, Sandra J. Lee, Krista M. Rubin, D. Lawrence +12 more
2017Cancer103 citations Open access
Semantic Scholar
Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition
Douglas B. Johnson, E. Pectasides, Emily Feld, Fei Ye +9 more
2017Journal of immunotherapy97 citations Open access
Semantic Scholar
VEGF neutralization plus CTLA-4 blockade alters soluble and cellular factors associated with enhancing lymphocyte infiltration and humoral recognition in melanoma
Xin-Qi Wu, A. Giobbie-Hurder, X. Liao, D. Lawrence +4 more
2016Cancer immunology research90 citations Open access
Semantic Scholar
Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial
F. Hodi, H. Kluger, M. Sznol, R. Carvajal +17 more
201688 citations
Semantic Scholar
Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors
Magid Awadalla, Doll Lauren Alexandra Golden, Syed S Mahmood, R. Alvi +33 more
2019Journal of Immunotherapy for Cancer78 citations Open access
Semantic Scholar
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
A. Ribas, A. Algazi, P. Ascierto, M. Butler +11 more
2020Nature Communications73 citations Open access
Semantic Scholar
Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.
M. Mooradian, M. Nasrallah, J. Gainor, K. Reynolds +6 more
2019Seminars in Arthritis & Rheumatism67 citations
Semantic Scholar
Combined anti-VEGF and anti–CTLA-4 therapy elicits humoral immunity to galectin-1 which is associated with favorable clinical outcomes
Xin-Qi Wu, Jingjing Li, E. Connolly, X. Liao +11 more
2017Cancer immunology research64 citations Open access
Semantic Scholar
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results
P. Brastianos, Albert E. Kim, A. Giobbie-Hurder, E. Lee +29 more
2023Nature Medicine55 citations Open access
Semantic Scholar
Benefit and toxicity of programmed death‐1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study *
Xue Bai, A. Shoushtari, Allison Betof Warner, L. Si +25 more
2022British Journal of Dermatology54 citations
Semantic Scholar
Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control.
Christopher A. Alvarez-Breckenridge, A. Giobbie-Hurder, C. Gill, Mia S. Bertalan +11 more
2019The Oncologist49 citations Open access
Semantic Scholar
Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study.
A. Ribas, F. Hodi, D. Lawrence, V. Atkinson +9 more
201649 citations
Semantic Scholar
Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series.
Jiahe Zheng, Z. Irani, D. Lawrence, K. Flaherty +1 more
2018Journal of Vascular and Interventional Radiology47 citations
Semantic Scholar
Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis
David A. Qualls, H. Seethapathy, Halla Bates, Shahein H. Tajmir +5 more
2019Journal of Immunotherapy for Cancer44 citations Open access
Semantic Scholar
Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors.
Lora R. Dagi Glass, D. Lawrence, F. Jakobiec, S. Freitag
2017Ophthalmic Plastic and Reconstructive Surgery44 citations
Semantic Scholar
1216OKEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma
A. Ribas, F. Hodi, D. Lawrence, V. Atkinson +9 more
201741 citations Open access
Semantic Scholar
Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations
P. Brastianos, Albert E. Kim, Nancy Wang, E. Lee +20 more
2021Nature Cancer40 citations Open access
Semantic Scholar
Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma
Samuel S. Freeman, M. Sade-Feldman, Jaegil Kim, Chip Stewart +35 more
2021bioRxiv39 citations Open access
Semantic Scholar
The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity
R. Rahman, A. Cortés, A. Niemierko, K. Oh +4 more
2018Journal of Neuro-Oncology39 citations
Semantic Scholar
Identification of fusions with potential clinical significance in melanoma
Jakob M. T. Moran, Long P. Le, V. Nardi, Josephine Golas +9 more
2022Modern Pathology36 citations Open access
Semantic Scholar
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study
J. Drago, D. Lawrence, E. Livingstone, L. Zimmer +9 more
2019Melanoma research33 citations Open access
Semantic Scholar
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
A. Tarhini, N. Kang, Sandra J. Lee, F. Hodi +17 more
2021Journal for ImmunoTherapy of Cancer30 citations Open access
Semantic Scholar
An Open-label, Dose-Escalation Phase 1 Study of anti-TYRP1 monoclonal antibody IMC-20D7S for patients with relapsed or refractory melanoma
D. Khalil, M. Postow, N. Ibrahim, D. Ludwig +10 more
2016Clinical Cancer Research29 citations Open access
Semantic Scholar
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma
M. Mooradian, A. Reuben, P. Prieto, M. Hazar-Rethinam +11 more
2018Oncoimmunology28 citations Open access
Semantic Scholar
A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status
B. Izar, W. Sharfman, F. Hodi, D. Lawrence +13 more
2017Cancer Medicine26 citations Open access
Semantic Scholar
Sinonasal Mucosal Melanoma: An Update and Review of the Literature.
B. Salari, R. Foreman, Kevin S. Emerick, D. Lawrence +1 more
2022American journal of dermatopathology24 citations
Semantic Scholar
Phase II study of pembrolizumab in leptomeningeal carcinomatosis.
P. Brastianos, S. Prakadan, Christopher A. Alvarez-Breckenridge, E. Lee +16 more
201821 citations
Semantic Scholar
Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.
S. Durbin, L. Zubiri, A. Niemierko, A. Bardia +10 more
2020The Oncologist20 citations Open access
Semantic Scholar
Rejection of benign melanocytic nevi by nevus-resident CD4+ T cells
Erik B. Schiferle, Se-Yun Cheon, Seokjin Ham, H. Son +8 more
2021Science Advances15 citations Open access
Semantic Scholar
United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.
A. Tarhini, Sandra J. Lee, F. Hodi, U. Rao +15 more
2019Journal of Clinical Oncology15 citations
Semantic Scholar
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial
P. Ott, Matthew Nazzaro, K. Pfaff, E. Gjini +11 more
2021Journal for ImmunoTherapy of Cancer14 citations Open access
Semantic Scholar
Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort
Xue Bai, Michelle S. Kim, Gyulnara G. Kasumova, L. Si +15 more
2021Journal for ImmunoTherapy of Cancer13 citations Open access
Semantic Scholar
Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum
A. Ameri, M. Mooradian, Kevin S. Emerick, J. C. Park +6 more
2019British Journal of Dermatology13 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Sullivan×28
Invite
R. Sullivan — researcher profile on SciRah
J. Cohen×16
Invite
J. Cohen — researcher profile on SciRah
K. Flaherty×14
Invite
K. Flaherty — researcher profile on SciRah
F. Hodi×13
Invite
F. Hodi — researcher profile on SciRah

A. Giobbie-Hurder

×11

Invite

A. Giobbie-Hurder — researcher profile on SciRah

Invite

K. Reynolds — researcher profile on SciRah

Invite

J. Sosman — researcher profile on SciRah

Invite

O. Hamid — researcher profile on SciRah

Dennie T. Frederick×7

Invite

Dennie T. Frederick — researcher profile on SciRah

Invite

G. Long — researcher profile on SciRah

D. McDermott×7

Invite

D. McDermott — researcher profile on SciRah

Invite

G. Boland — researcher profile on SciRah